BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)

ALAMEDA, Calif.--()--BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that BioTime, and its subsidiary Cell Cure Neurosciences Ltd., will be featured in two presentations at the 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED) on Wednesday, May 24, 2017 as part of the Regenerative and Cell Therapies track. The conference is being held at the David InterContinental in Tel Aviv, Israel, May 23-25, 2017.

Presentations will be held at 12:15 p.m. and 3:45 p.m. IDT in Hall B of the InterContinental, and will highlight both the company’s technology and business model. Jim Knight, BioTime, Inc. Senior Vice President and Head of Corporate Development, will discuss the evolution of the BioTime group of companies during one of the presentations. A second presentation will focus on cell-based transplantation therapy in AMD patients. Each presentation will be followed by a panel discussion. More information about the conference program and presentations can be found here.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company believes to be the world’s premier collection of pluripotent cell assets. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation, which BioTime founded and which, until recently, were majority-owned consolidated subsidiaries of BioTime.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

Contacts

Investor Contact:
EVC Group, Inc.
Michael Polyviou/Doug Sherk, 646-445-4800
mpolyviou@evcgroup.comdsherk@evcgroup.com
or
Media Contact:
JQA Partners, Inc.
Jules Abraham, 917-885-7378
jabraham@jqapartners.com

Recent Stories

RSS feed for BioTime, Inc.

BioTime, Inc.